by michaelhalassa | May 14, 2025 | Cobenfy, KarXT
What Cobenfy Teaches Us About the Future of Psychiatric Drug Development The approval of Cobenfy (xanomeline-trospium) marks more than just the arrival of a new antipsychotic. It’s a signal—subtle but decisive—that the center of gravity in psychiatry may be shifting....
by michaelhalassa | Mar 11, 2025 | Cobenfy, Schizophrenia treatment, Trospium, Xanomeline
The Story of Tim: A Turning Point Tim, a young man in his mid-20s, had been struggling with schizophrenia for years. Despite multiple antipsychotic trials, his symptoms remained poorly controlled. He experienced severe side effects—weight gain, sedation, and...
